(0.34%) 5 117.13 points
(0.33%) 38 365 points
(0.38%) 15 989 points
(-0.98%) $83.03
(5.25%) $2.02
(0.35%) $2 355.30
(0.48%) $27.67
(4.09%) $959.85
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
@ $11.85
発行日: 15 2月 2024 @ 03:14
リターン: -18.31%
前回のシグナル: 2月 14 - 02:38
前回のシグナル:
リターン: 1.28 %
Live Chart Being Loaded With Signals
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK...
Stats | |
---|---|
本日の出来高 | 19 755.00 |
平均出来高 | 143 859 |
時価総額 | 244.86M |
EPS | $0 ( 2024-03-12 ) |
次の収益日 | ( $-1.160 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.44 |
ATR14 | $0.0390 (0.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Calkins Daniel | Sell | 6 | Common Stock |
2024-03-25 | Calkins Daniel | Sell | 25 | Common Stock |
2024-03-20 | Calkins Daniel | Sell | 55 | Common Stock |
2024-03-18 | Gagnon Robert E. | Sell | 283 | Common Stock |
2024-03-19 | Gagnon Robert E. | Sell | 130 | Common Stock |
INSIDER POWER |
---|
50.18 |
Last 99 transactions |
Buy: 1 037 036 | Sell: 241 539 |
ボリューム 相関
Verastem Inc 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Verastem Inc 相関 - 通貨/商品
Verastem Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2023 |
収益: | $0 |
総利益: | $-62 000.00 (0.00 %) |
EPS: | $-3.96 |
FY | 2022 |
収益: | $2.60M |
総利益: | $2.48M (95.45 %) |
EPS: | $-4.58 |
FY | 2021 |
収益: | $2.05M |
総利益: | $2.05M (100.00 %) |
EPS: | $-0.464 |
Financial Reports:
No articles found.
Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。